Lakewood-Amedex Biotherapeutics is a clinical-stage biopharmaceutical company developing a novel class of antimicrobial drugs called Bisphosphocins to treat antibiotic-resistant bacterial infections. The company has no revenue and has not commercialized any product. Its lead candidate, Nu-3, is a topical gel targeting mildly infected diabetic foot ulcers (iDFU), a condition affecting a large share of diabetic patients and carrying significant amputation risk. The company argues that oral antibiotics — the current standard of care — are often unreliable in iDFU due to poor circulation in diabetic extremities, creating an opportunity for a directly applied topical agent. Lakewood-Amedex completed a Phase 1/2a study of Nu-3 showing positive trends in antimicrobial response, and plans to advance into Phase 2a and Phase 2b trials. Beyond iDFU, the company is pursuing catheter-associated urinary tract infections and pulmonary infections at preclinical stages using other Bisphosphocin compounds. Lakewood-Amedex has 5 full-time employees and outsources manufacturing and clinical trial execution to third-party contractors. The company has raised $46.1M in gross proceeds since inception, most recently closing a $7.5M Series C financing in April 2026 to fund the Phase 2a trial. With an accumulated deficit of $53.4M and a going concern qualification from auditors, Lakewood-Amedex will need substantial additional capital to advance through later-stage trials and commercialization.